GNS Healthcare, Dana Farber, Mount Sinai to Collaborate on In Silico Multiple Myeloma Models | GenomeWeb

GNS Healthcare said this week that it is collaborating with Dana-Farber Cancer Institute and Mount Sinai School of Medicine to build computer models of multiple myeloma using the company’s reverse engineering and forward simulation platform.

The partners will use GNS’ REFS platform to engineer network models from next-generation sequencing data as well as proteomic data, information on patient outcomes, and other clinical data.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PNAS this week: researchers identify the characteristic genomic features of clear cell renal cell carcinoma, and more.

A technology that has the potential to make species go extinct could be used against the Zika virus. 

University of the Republic postdoc Victor Morais says researchers should be careful of the open access journals they choose to publish in.

If science funding agencies can talk tough about sexual harassers, shouldn't they also put their talk into action?

Feb
25
Sponsored by
Omicia

This webinar will demonstrate how ACMG's recommended variant scoring and classification rules may be applied to standardize reporting on sequencing test results within and across institutions.